Melodiol Global Health (ASX:ME1DE) Total Liabilities : A$23.10 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Total Liabilities?

Melodiol Global Health's Total Liabilities for the quarter that ended in Dec. 2023 was A$23.10 Mil.

Melodiol Global Health's quarterly Total Liabilities increased from Dec. 2022 (A$15.69 Mil) to Jun. 2023 (A$23.76 Mil) but then declined from Jun. 2023 (A$23.76 Mil) to Dec. 2023 (A$23.10 Mil).

Melodiol Global Health's annual Total Liabilities increased from Dec. 2021 (A$1.56 Mil) to Dec. 2022 (A$15.69 Mil) and increased from Dec. 2022 (A$15.69 Mil) to Dec. 2023 (A$23.10 Mil).

Melodiol Global Health Total Liabilities Historical Data

The historical data trend for Melodiol Global Health's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Total Liabilities Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

5.39

5.47

1.56

15.69

23.10

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial										1.56	3.16	15.69	23.76	23.10

Melodiol Global Health Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Melodiol Global Health's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	23.018	+	(0.084	+	-3.7470027081099E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	23.10

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	19.044	-	-4.058
	=	23.10

Melodiol Global Health's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	23.018	+	(0.084	+	-3.7470027081099E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	23.10

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	19.044	-	-4.058
	=	23.10

Melodiol Global Health Total Liabilities Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (ASX:ME1DE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

COPHF:USA

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines